- Home
- CELC vs DGICA Comparison
CELC vs DGICA Comparison
Compare CELC & DGICA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- DGICA
- Stock Information
- Founded
- CELC 2011
- DGICA 1986
- Country
- CELC United States
- DGICA United States
- Employees
- CELC N/A
- DGICA N/A
- Industry
- CELC Medical Specialities
- DGICA Property-Casualty Insurers
- Sector
- CELC Health Care
- DGICA Finance
- Exchange
- CELC Nasdaq
- DGICA Nasdaq
- Market Cap
- CELC 594.7M
- DGICA 516.7M
- IPO Year
- CELC 2017
- DGICA N/A
- Fundamental
- Price
- CELC $12.66
- DGICA $15.79
- Analyst Decision
- CELC Strong Buy
- DGICA
- Analyst Count
- CELC 6
- DGICA 0
- Target Price
- CELC $29.17
- DGICA N/A
- AVG Volume (30 Days)
- CELC 257.7K
- DGICA 85.4K
- Earning Date
- CELC 11-14-2024
- DGICA 10-24-2024
- Dividend Yield
- CELC N/A
- DGICA 4.37%
- EPS Growth
- CELC N/A
- DGICA 148.60
- EPS
- CELC N/A
- DGICA 0.74
- Revenue
- CELC N/A
- DGICA $979,119,004.00
- Revenue This Year
- CELC N/A
- DGICA N/A
- Revenue Next Year
- CELC N/A
- DGICA $6.66
- P/E Ratio
- CELC N/A
- DGICA $21.20
- Revenue Growth
- CELC N/A
- DGICA 7.44
- 52 Week Low
- CELC $11.51
- DGICA $12.26
- 52 Week High
- CELC $22.19
- DGICA $16.00
- Technical
- Relative Strength Index (RSI)
- CELC 28.22
- DGICA 60.16
- Support Level
- CELC $15.33
- DGICA $14.62
- Resistance Level
- CELC $16.14
- DGICA $15.67
- Average True Range (ATR)
- CELC 0.97
- DGICA 0.41
- MACD
- CELC -0.28
- DGICA 0.03
- Stochastic Oscillator
- CELC 22.85
- DGICA 84.78
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.